result detected in the complete cohort. Recently, a systematic review identified a total of 13 studies that have described CMV infection in immunocompetent critically ill patients. CMV infection occurred in 0% to 36% of these critically ill patients. The authors found considerable heterogeneity in the methodology used to assess CMV infection and in the study population, which can explain the variability of the results. Our study has some limitations, including relatively low Acute Physiology and Chronic Health Evaluation (APACHE II) scores for each group, despite a relatively long length of stay in the ICU.

In conclusion, despite the use of a very sensitive PCR assay, we were unable to demonstrate a significant prevalence of CMV viremia in our nonimmunocompromised ICU population. Accordingly, our data do not support empiric screening of nonimmunocompromised ICU patients in the absence of clinical evidence of CMV infection.

Élise Gilbert, MD
Philippe Rico, MD
Pierre J. Lafllamme, MD
Martin Albert, MD
Montreal, QC, Canada

Affiliations: From the Intensive Care Department (Drs Gilbert, Rico, and Albert); the Internal Medicine Department (Drs Rico and Albert); and the Infectious Disease Department (Dr Lafllamme); Hôpital du Sacré-Coeur de Montréal Research Centre; Université de Montréal.

Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Funding/Support: This work was supported by the Équipe de Recherche en Soins Intensifs (ERESI) de l’Hôpital du Sacré-Coeur de Montréal Research Fund. The CMV PCR assay was supported by Hoffmann-La Roche Ltd.

Correspondence to: Martin Albert, MD, Intensive Care Department and Internal Medicine Department, Hôpital du Sacré-Coeur de Montréal Research Center, Université de Montréal, 5400, boul. Gouin Ouest, Montréal, QC H4J 1C5, Canada; e-mail: m.albert@umontreal.ca

© 2011 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprintx.shtml).

DOI: 10.1378/chest.10-2290

Table 1—Patient Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Group A</th>
<th>Group B</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>58.0 ± 17.6</td>
<td>46.5 ± 23.0</td>
<td>52.4 ± 21.0</td>
</tr>
<tr>
<td>Length of stay, d</td>
<td>19 ± 43</td>
<td>23 ± 11</td>
<td>20.9 ± 31</td>
</tr>
<tr>
<td>Admission unit</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trauma</td>
<td>17 (34)</td>
<td>22 (44)</td>
<td>39 (30)</td>
</tr>
<tr>
<td>General Surgery</td>
<td>14 (30)</td>
<td>10 (20)</td>
<td>24 (24)</td>
</tr>
<tr>
<td>Medical</td>
<td>9 (18)</td>
<td>10 (20)</td>
<td>19 (19)</td>
</tr>
<tr>
<td>Cardiovascular Surgery</td>
<td>9 (18)</td>
<td>8 (16)</td>
<td>17 (17)</td>
</tr>
<tr>
<td>APACHE II score</td>
<td>18 ± 9</td>
<td>20 ± 6</td>
<td>19 ± 8</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>15 (30)</td>
<td>18 (36)</td>
<td>33 (33)</td>
</tr>
<tr>
<td>Antibiotic</td>
<td>45 (90)</td>
<td>47 (94)</td>
<td>92 (92)</td>
</tr>
<tr>
<td>Duration, d</td>
<td>11.3 ± 8.2</td>
<td>14.8 ± 11.0</td>
<td></td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>44 (88)</td>
<td>45 (96)</td>
<td>92 (92)</td>
</tr>
<tr>
<td>Mortality</td>
<td>7.14</td>
<td>7.14</td>
<td>14 (14)</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD or No. (%). Group A: baseline 5 d of ICU admission; Group B: baseline 10 d of ICU admission. APACHE = Acute Physiology and Chronic Health Evaluation.

ACKNOWLEDGMENTS

Author contributions: Dr Albert had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Dr Gilbert: contributed to the study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content.

Dr Rico: contributed to the study concept and design, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content.

Dr Lafllamme: contributed to the study concept and design, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content.

Dr Albert: contributed to the study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content.

Role of Sponsors: The CMV-PCR assays were graciously provided by Roche Inc, which had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.

REFERENCES


Low-Dose Tissue Plasminogen Activator in Pulmonary Embolism

Benefit Remains Unclear

To the Editor:

We read the article in CHEST (February 2010) by Wang et al1 with great interest. However, we found several limitations. First, the authors tried to demonstrate the equivalency of low-dose and full-dose tissue plasminogen activator (tPA), although the superiority of full-dose tPA compared with anticoagulation in pulmonary embolism with right ventricular dysfunction is not firmly established, and its use remains controversial. The pulmonary embolism thrombolysis study, a large, ongoing European multicenter randomized controlled trial, will hopefully settle the controversy.

Second, the authors used a CT pulmonary angiography score as one of the surrogate end points. However, it is unclear whether...
this score is an adequate predictor of poor clinical outcome.\textsuperscript{2}
To our knowledge, the correlation between this score and clinical outcome has never been validated in the setting of thrombolysis, and the use of surrogate end points in clinical research remains controversial.\textsuperscript{3}

Third, the authors did not report the interobserver agreement (k value) in their study. Previous studies have found a low interobserver agreement for the assessment of the surrogate end points chosen.\textsuperscript{2}

Lastly, the authors used a difference of 10 points in CT pulmonary angiography score to calculate the sample size, without providing the rationale for using such a difference. It is not clear whether such a difference is clinically relevant. Moreover, they did not specify the margins of noninferiority and nonsuperiority, and the study seems grossly underpowered to test the equivalence.\textsuperscript{4}

In an equivalence trial, both participants and outcome measures should be similar to those in the trial(s) that established the efficacy of the reference treatment (100 mg tPA, in this case).\textsuperscript{5}

\textit{Shigeki Saito, MD}
Stanford, CA

\textit{Basal Altaqi, MD}

\textit{Francesco Simeone, MD}
New Orleans, LA

\textbf{Affiliations:} From the Department of Medicine (Dr Saito), Stanford University; and the Department of Medicine (Drs Altaqi and Simeone), Tulane University.

\textbf{Financial/nonfinancial disclosures:} The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

\textbf{Correspondence to:} Shigeki Saito, MD, Stanford University, 300 Pasteur Dr, H3143, Stanford, CA 94305; e-mail: shigekis@stanford.edu

\textcopyright 2011 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).

\textbf{DOI:} 10.1378/chest.10-2333

\textbf{References}


